Organogenesis director sells 200,000 shares of Class A stock

Organogenesis Holdings Inc. reported an insider stock transaction by a company director.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. reported an insider stock transaction by a company director. On 12/16/2025, the director sold 200,000 shares of Class A Common Stock in open-market trades at a weighted-average price of $5.1353 per share, with individual trade prices ranging from $5.10 to $5.24.

After this sale, the director directly beneficially owns 2,565,591 shares of Class A Common Stock. In addition, the director has indirect beneficial ownership through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares of Class A Common Stock, respectively.

Insider Trade Summary

Net Seller: 200,000 shares

Net Sell 4 txns

Insider NUSSDORF GLENN H

Role Director

Sold 200,000 shs ($1.03M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	200,000	$5.1353	$1.03M
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 2,565,591 shares (Direct); Class A Common Stock — 918,680 shares (Indirect, By GN 2016 Family Trust u/a/d August 12, 2016); Class A Common Stock — 7,928,570 shares (Indirect, By GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016); Class A Common Stock — 335,719 shares (Indirect, By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.24, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Organogenesis (ORGO) report in this filing?

The filing reports that a director of Organogenesis Holdings Inc. sold 200,000 shares of Class A Common Stock in an open-market transaction on 12/16/2025.

At what price were the Organogenesis (ORGO) shares sold by the director?

The 200,000 shares were sold at a weighted-average price of $5.1353 per share, in multiple trades at prices ranging from $5.10 to $5.24.

How many Organogenesis (ORGO) shares does the director own after the sale?

Following the reported sale, the director directly beneficially owns 2,565,591 shares of Organogenesis Class A Common Stock.

What additional Organogenesis (ORGO) shares does the director hold indirectly through trusts?

The director has indirect beneficial ownership of Organogenesis Class A Common Stock through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares, respectively.

What is the director’s relationship to Organogenesis Holdings Inc. (ORGO)?

The reporting person in this filing is identified as a Director of Organogenesis Holdings Inc., as indicated in the relationship section.

How were the Organogenesis (ORGO) share sale prices disclosed?

The filing states that the price in the table is a weighted-average price and notes the shares were sold in multiple transactions at prices between $5.10 and $5.24.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NUSSDORF GLENN H

(Last) (First) (Middle)

35 SAWGRASS DRIVE

(Street)

BELLPORT NY 11713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/16/2025		S		200,000	D	$5.1353(1)	2,565,591	D
Class A Common Stock								918,680	I	By GN 2016 Family Trust u/a/d August 12, 2016
Class A Common Stock								7,928,570	I	By GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016
Class A Common Stock								335,719	I	By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.24, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

	/s/ William R. Kolb, Attorney-in-Fact	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.